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The abnormal megakaryocytopoiesis associated with
idiopathic myelofibrosis (IM) plays a role in its patho-
genesis. Because mice with defective expression of
transcription factor GATA-1 (GATA-1low mutants)
eventually develop myelofibrosis, we investigated the
occurrence of GATA-1 abnormalities in IM patients.
CD34 cells were purified from 12 IM patients and 8
controls; erythroblasts and megakaryocytes were
then obtained from unilineage cultures of CD34
cells. Purified CD61, GPA, and CD34 cells from IM
patients contained levels of GATA-1, GATA-2, and
FOG-1 mRNA, as well as of GATA-2 protein, that were
similar to controls. In contrast, CD61 cells from IM
patients contained significantly reduced GATA-1 pro-
tein. Furthermore, 45% of megakaryocytes in biop-
sies from IM patients did not stain with anti-GATA-1
antibody, as compared to controls (2%), essential
thrombocythemia (4%), or polycythemia vera (11%)
patients. Abnormalities in immunoreactivity for
FOG-1 were not found, and no mutations in GATA-1
coding sequences were found. The presence of GATA-
1neg megakaryocytes in bone marrow biopsies was
independent of the Val617Phe JAK2 mutation, mak-
ing it unlikely that a downstream functional relation-
ship exists. We conclude that megakaryocytes from
IM patients have reduced GATA-1 content, possibly
contributing to disease pathogenesis as in the GATA-
1low mice and also representing a novel IM-associated
marker. (Am J Pathol 2005, 167:849–858)
Chronic idiopathic myelofibrosis (IM; ICD-O9961/3), ac-
cording to the World Health Organization classification of
tumors of hematopoietic and lymphoid tissues,1 is the
least frequent among chronic myeloproliferative disor-
ders (CMPDs), with an estimated incidence of0.5 to 1.5
new cases per 100,000 individuals per year. It is a clonal
disorder of the multipotent hematopoietic stem cell, char-
acterized by accumulation of abnormal megakaryocytes
in the marrow and progressive structural changes of the
microenvironment, which include extensive collagen and
reticulin deposition, osteosclerosis, and angiogenesis.2,3
Foci of extramedullary hematopoiesis may develop in
several organs, mostly the spleen and the liver. The blood
film of these patients is characterized by a leuko-erythro-
blastic picture, with immature myeloid and erythroid cells,
and by tear-drop erythrocytes.4 The CD34 hematopoi-
etic progenitor cells are constitutively mobilized in the
peripheral blood,5,6 and their number may be related to
the severity of the disease and the risk of leukemic trans-
formation;6,7 the latter occurs in 5 to 20% of patients,8,9
with a dismal outcome.8 The changes in bone marrow
(BM) stroma are the result of a response of local fibro-
blasts, that remain polyclonal and do not derive from the
neoplastic clone,10 to cytokines, such as transforming
growth factor-1, released by the abnormal megakaryo-
cytes.11,12 Clinical course and overall survival are greatly
variable, depending on prognostic scores.13 At present,
the only curative approach is represented by allogeneic
hematopoietic stem cell transplantation,14 either conven-
tional or reduced intensity, that can be sadly offered to a
minority of younger patients. Cytogenetic abnormalities
occur in almost 50% of patients at diagnosis and in-
crease further in the follow-up,15 but they are not recur-
rent nor have they been clearly associated with the
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pathogenesis of disease, leaving its primary molecular
defect still unknown. However, the recent description of a
Val617Phe mutation in the exon 12 of JAK2 gene may
represent the first reliable molecular marker of IM16–18
although, unlike in polycythemia vera (PV) in which 74 to
97% of patients presented the mutation, only 35 to 57% of
those with IM were Val617Phepositive, a figure comparable
to the finding in essential thrombocythemia (ET) (32 to
50%); intriguingly, this suggests that other molecular
pathway(s) in addition to those depending on Jak2,
and/or individual genetic characteristics, might be re-
sponsible for the unique clinical phenotype of IM in re-
spect to either PV or ET.
Insights into the pathogenesis of IM derived from the
observation that mice with induced alterations in the reg-
ulation of megakaryocytopoiesis develop a myelofibrosis-
like syndrome.19 Mice chronically exposed to high levels
of the megakaryocytic-specific growth factor thrombopoi-
etin (TPO) after transplantation with BM cells infected with
a retrovirus containing the TPO gene20–22 show throm-
bocytosis and develop within a few months a myelofibro-
sis-like syndrome, terminating in acute leukemia in some
animals.20 The development of a phenotype resembling
human IM has been documented also in mice genetically
modified at the GATA-1 locus (GATA-1low mutation).23,24
GATA-1 is the founder of a six-member family of tran-
scription factors that, by binding to the consensus se-
quences (A/T)GATA(A/G) in the promoter and enhancer
regions of target genes, regulates proliferation and dif-
ferentiation of erythroid, megakaryocytic, eosinophilic,
and mast cells.25 In erythroid and megakaryocytic cells,
GATA-1 binds to its cognate sequences as an obligatory
dimer of FOG-1 (for friend-of-GATA-1)25 and both the
FOG-1null and the GATA-1null mutation in mice cause
embryonic lethality because of fatal anemia.26,27 The
GATA-1low mice were developed in Dr. S. Orkin’s labora-
tory (Children’s Hospital, Boston, MA)23 through the tar-
geted deletion of regulatory sequences in the GATA-1
locus, that include the DNase hypersensitivity site I (HS I).
The mutation totally abolished GATA-1 expression in
megakaryocytes and strongly reduced it in erythroid28
and mast cells.29 GATA-1low mice suffer from a life-long
severe thrombocytopenia due to complex defects in
megakaryocyte maturation, that under several respects
resemble those observed in IM patients.30,31 These in-
clude abnormal P-selectin localization on the demarca-
tion membrane system, increased neutrophil emperipole-
sis with the subsequent release in the microenvironment
of neutrophil proteases as well as of transforming growth
factor-1 produced by megakaryocytes, and death by
para-apoptosis.32 Old (15 months on) GATA-1low mice
show features resembling human IM, that include: severe
marrow fibrosis, osteosclerosis, thrombocytopenia and
tear-drop poikilocytes on blood films, an increased num-
ber of circulating hematopoietic progenitors, splenomeg-
aly, and extramedullary hematopoiesis.24
Although alterations of the TPO receptor or of TPO
regulatory pathways have not been documented in a
well-characterized series of IM patients,33 it has not been
addressed thoroughly whether GATA-1 is mutated or
abnormally expressed in IM.34 We show here that
megakaryocytes from IM patients, either examined in vitro
or ex vivo in core biopsies, contain reduced levels of
GATA-1 protein when compared to control cells, as it has
been reported in the GATA-1low mice.24 Because this
deficiency does not involve two other megakaryocytopoi-
etic transcription factors, GATA-2 and FOG-1, we sug-
gest that defective expression of GATA-1 represents a
selective abnormality of IM megakaryocytes eventually
contributing to the pathogenesis of the disease, and also
constitutes a novel marker with potential diagnostic
implications.
Patients and Methods
Study Participants
IM patients12 were diagnosed according to the following
consensus criteria:35 as obligatory criteria, diffuse mar-
row fibrosis and absence of BCR-ABL rearrangement; as
accessory criteria, splenomegaly, teardrop erythrocytes,
circulating immature myeloid cells and erythroblasts, and
clusters of abnormal megakaryocytes in BM biopsy. Their
clinical features at the time of blood sampling are sum-
marized in Table 1. They were all chemotherapy-free and
Table 1. Patients’ Characteristics at the Time of Blood Sampling for This Study
Patient
no./sex
Lillie
score13
Time since
diagnosis (years)
RBC transfusion
requirement
Circulating CD34 cells
(106/L)
White blood cells
(109/L)
Hemoglobin
(g/L)
Platelets
(109/L)
1/M 1 0.2 No 38 7.5 128 213
2/F 1 5 Yes 468 2.2 58 7
3/F 0 2 Yes 98 4.7 105 81
4/M 0 3 No 379 9.4 113 350
5/M 1 2 Yes 55 17.7 85 226
6/F 1 1 No 45 37.7 121 472
7/M 0 1 Yes 38 6.7 118 305
8/M 0 1.5 No 27 23.5 135 198
9/M 1 2 Yes 800 11.8 95 120
10/M 2 3 Yes 180 32.2 87 200
11/F 0 1 No 50 13.3 128 43
12/M 2 0.5 Yes 285 2.2 79 253
Median 76.5 10.6 109 206
(range) (27 to 800) (2.2 to 37.7) (58 to 135) (7 to 472)
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7 of 12 received supportive treatment or low-dose pred-
nisone. They all presented high numbers of circulating
CD34 cells (median, 76.5; range, 27 to 800  106/L); in
three of them (patients 2, 4, 9), CD34 count was more
than the 300  106/L value that has been associated with
greater risk of leukemic transformation,6 yet at 6 to 9
months after blood sampling for this study their disease
was still in chronic phase. On histopathological evalua-
tion, all patients were in a typical fibrotic stage of dis-
ease.1 The study included as controls 8 healthy BM
donors, 10 patients with solid tumors without BM involve-
ment, and patients with two other Philadelphia-negative
CMPDs, PV (10 patients) and ET (10 patients), diagnosed
according to the World Health Organization criteria.1
Samples from PV and ET patients were obtained at the
time of diagnosis. The study had received the approval
from the local Ethical Committee; an informed consent
was obtained from each one of the study participants
involved at the time of sample collection.
Cell Purification and Culture
CD34 cells were purified from 30 to 50 ml of peripheral
blood collected from IM patients in ethylenediamine tet-
raacetic acid tubes or from BM aspirates from healthy
donors in preservative-free heparin. In both cases, mono-
nuclear cells were separated over a Ficoll gradient (Lym-
phoprep; Nycomed Pharma, Oslo, Norway), and pro-
cessed through two sequential steps of immunomagnetic
CD34 selection (Miltenyi Biotech, Gladbach, Germany).
The purity of the CD34 cell population isolated with this
procedure was assessed by flow cytometry (FACScan
flow cytometer; Becton Dickinson, San Diego, CA) after
labeling with a phycoerythrin-conjugated anti-CD34
monoclonal antibody (PE-HPCA2, Becton-Dickinson). Ali-
quots of CD34 cells were either immediately resus-
pended in lysis buffer for RNA purification (see below) or
placed in culture. Liquid cultures were established in
six-well plates by culturing 105 CD34 cells/ml in serum-
free medium (StemSpan; StemCell Technologies; Van-
couver, Canada) supplemented with either human re-
combinant TPO (50 ng/ml), for unilineage megakaryocyte
differentiation, or human recombinant erythropoietin (3
U/ml), stem cell factor (2.5 ng/ml), and interleukin-3 (5
ng/ml; all from Sigma-Aldrich, St. Louis, MO), for erythroid
differentiation. The cultures were supplemented with
fresh cytokines every other day. After 14 to 16 days of
culture, 70% or 80% of the cells in the two systems
expressed megakaryocytic (CD41/CD61) or erythroid
(glycophorin-A; GPA) markers, respectively, by fluores-
cence-activated cell sorting analysis. Erythroid and
megakaryocytic cells were further purified by immuno-
magnetic selection with anti-GPA- or anti-CD61-coated
magnetic microbeads (Miltenyi Biotech).
mRNA Analysis
Total RNA was isolated from purified cells with a guani-
dine thiocyanate/phenol solution (Trizol; Gibco BRL, Pais-
ley, UK) and quantified by UV absorbance at 280/260
nm. The expression level of genes of interest was deter-
mined by quantitative real-time polymerase chain reac-
tion (PCR). Total RNA (1 g) was reverse-transcribed
with random hexamers and the resulting cDNA (50 ng/
tube) was amplified in a ABI PRISM 7700 sequence
detection system (Applied Biosystems, Foster City, CA)
using the following parameters: 40 cycles of a two-step
PCR program at 95°C for 15 seconds and 60°C for 60
seconds, after an initial denaturation/activation step at
95°C for 10 minutes. The sequence of primers for
GATA-1, GATA-2, and FOG-1, and of corresponding
probes labeled with TAMRA-FAM, is reported in Table 2.
To normalize expression levels in different cell samples,
mRNA of the housekeeping GAPDH gene was concur-
rently amplified (Pre-Developed TaqMan Assay Reagent,
Applied Biosystem). The SDS software was used to ana-
lyze fluorescent signals and to calculate the cycle thresh-
old (CT); quantitative normalization of cDNA in each sam-
Table 2. Primers Used for PCR Analysis
GATA-1 forward primer: 5 CAAGAAGCGCCTGATTGTCAG 3
GATA-1 reverse primer: 5 AGTGTCGTGGTGGTCGTCTG 3
GATA-1 probe: 5 AAACGGGCAGGTACTCAGTGCACCAACT 3
Amplified fragment size: 71 bp
GATA-2 forward primer: 5 ATCCAGACTCGGAACCGGA 3
GATA-2 reverse primer: 5 GCACTTTGACAGCTCCTCGAA 3
GATA-2 probe: 5 ATGTCCAACAAGTCCAAGAAGAGCAAGAAAGG 3
Amplified fragment size: 83 bp
FOG-1 forward primer: 5 TTGCCACCGCAGTGATCA 3
FOG-1 reverse primer: 5 GCTCGCTGCGGTACCAGAT 3
FOG-1 probe: 5 AGACGTCTTCCCCTGCAAGGACTGTG 3
Amplified fragment size: 68 bp
GATA-1 alternative transcripts36
Exon 1 forward primer: 5 AGGACACCCCCTGGGATC 3
Exon 3 reverse primer: 5 CTCCATACAGTTGAGCAATGGG 3
Amplified fragment size (full-length cDNA): 384 bp
Amplified fragment size (alternative splice variant cDNA): 109 bp
JAK2 mutation analysis16
Reverse primer: 5 CTGAATAGTCCTACAGTGTTTTCAGTTTCA 3
Forward (specific): 5 AGCATTTGGTTTTAAATTATGGAGTATATT 3
Forward (internal control): 5 ATCTATAGTCATGCTGAAAGTAGGAGAAAG 3
GATA-1 Abnormalities in IM 851
AJP September 2005, Vol. 167, No. 3
ple was obtained by the CT method (target gene CT 
GAPDH CT). Each sample was assayed in triplicate, and
both a negative (mock cDNA) and a positive (cDNA from
cord blood mononuclear cells) control were used in each
assay for reproducibility accuracy.
The expression of the two human GATA-1 mRNA tran-
scripts was assessed by reverse transcriptase (RT)-PCR,
starting from 200 ng of cDNA, using a forward primer
from exon 1 and a reverse primer from exon 3 (Table 2).36
Amplification was performed at 63°C in a GeneAmp 9700
Perkin-Elmer thermocycler and samples were analyzed
after 25, 28, 31, and 33 cycles to be in the linear range of
amplification. Positive and negative controls were in-
cluded in each experiment. Amplified products were re-
solved by 2.5% agarose gel electrophoresis and stained
with ethidium bromide; UV-light images were acquired
and analyzed with the Kodak EDAS290 analyzer (East-
man Kodak Company, New Haven, CT).
Protein Analysis
To cope with the limiting number of purified cells ob-
tained from a single individual, an equal number of cells
was pooled from each of three (IM patients) to four (con-
trol) patients. Proteins were extracted from CD34,
GPA, and CD61 cells in the presence of protease
inhibitor cocktail (Sigma Aldrich). Aliquots containing
50 g of proteins were resolved by 10% sodium dode-
cyl sulfate-polyacrylamide gel electrophoresis and trans-
ferred to Hybond ECL-nitrocellulose membrane (Amer-
sham Biosciences, Piscataway, NJ). After blocking, the
blots were incubated with either the rat monoclonal anti-
GATA-1 (0.8 g/ml, N6) or anti-GATA-2 antibody (H-116;
both from Santa Cruz Biotechnology, Santa Cruz, CA),
followed by incubation with peroxidase-conjugated rab-
bit anti-rat secondary antibody. In some experiments,
blots were also reprobed with a goat polyclonal antibody
(C20) that recognizes the C-terminus of GATA-1 with the
aim to identify the shorter isoform. The blots were devel-
oped with enhanced chemiluminescence (West Pico;
Pierce, Rockford, IL), and exposed to ECL-hyperfilms
(Amersham) for 1 to 5 minutes. Protein loading was
checked by reprobing stripped blots with goat anti-actin
antibody (sc-1615, Santa Cruz); relative quantification of
GATA-1/2 versus actin levels was obtained by scanning
the films with the Kodak EDAS290 analyzer.
GATA-1 Sequencing
DNA was extracted from purified CD34; 100 ng of DNA
were amplified using experimental conditions and prim-
ers described.37 PCR products were prepared with the
QIAquick PCR purification kit (Qiagen, GmbH, Germany)
and sequenced directly using the BigDye terminator sys-
tem and the ABI 310 analyzer (Applied Biosystem).
JAK2 Mutation Analysis
This was performed essentially as described.16 Briefly,
100 ng of DNA purified from granulocytes was amplified
at 58°C for 38 cycles in an allele-specific PCR (the
sequence of primers is reported in Table 2); amplified
fragments were resolved in a 2.5% agarose gel and
visualized under ethidium-bromide staining. A 364-bp
amplified product was derived from both normal and
mutant allele whereas the 203-bp product specifically
originated from the mutant allele.
Immunohistochemistry on BM Biopsies
BM biopsies were obtained by standard procedures and
embedded in paraffin. After antigen retrieval, slides were
incubated with monoclonal rat anti-GATA-1 or polyclonal
rabbit anti-FOG-1 (kindly donated by Dr. K. Freson, Uni-
versity of Leuven, Leuven, Belgium)38 antibody. Immuno-
reactivity was developed with the Ultrastain polyvalent
peroxidase immunostaining kit (Ylem, Rome, Italy). Slides
not incubated with the primary antibody served as neg-
ative controls. Sections were analyzed with a Leica Light
Microscope (Leica LTD, Heidelberg, Germany) equipped
with a Coolsnap video camera for computerized images
(RS Photometrics, Tucson, AZ). To minimize staining vari-
ability, slides from both controls and IM patients were
concurrently processed and independently evaluated by
two observers who were blinded of clinical diagnosis
(observer intervariability 10%). GATA-1/FOG-1 staining
was determined by analyzing all of the megakaryocytes
found in randomly selected fields at 40 up to at least
100 megakaryocytes/sample. Megakaryocytes were
classified as GATA-1pos if they showed clearly stained
nuclei  cytoplasm, and GATA-1neg if both nucleus and
cytoplasm exhibited no to very faint immunoreactivity.
Statistical Analysis
Statistical evaluations of data were performed using the
SPSS statistical software package (release 11.5.1; SPSS,
Chicago, IL). Analysis of variance, Mann-Whitney U-test,
or Fisher exact test were used for direct comparison, as
appropriate. For all of the comparisons, the P value was
two-tailed, and a P  0.05 was exhibited as statistically
significant.
Results
Due to the high number of circulating CD34 cells, in all
of the IM patients included in this study it was feasible to
isolate to high purity (97  2%) a number of CD34 cells
(range, 2.1 to 20  106) sufficient for RNA analysis
and for seeding unilineage cultures. At the end of the
culture, purified erythroid (GPA, purity 94  3%) and
megakaryocytic (CD61, purity 93 4%) cells in number
sufficient for further analysis (range, 0.9 to 3.3 106 cells
starting from 0.2 to 4  106 CD34 cells) were obtained
from all of the normal donors (n 	 8) and from 11 of 12
and 10 of 12 IM patients, respectively. Representative
images of fluorescence-activated cell sorting histograms
and morphology of the purified cell populations analyzed
are shown in Figure 1A.
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The results of real-time PCR analysis for the quantita-
tive determination of GATA-1, FOG-1, and GATA-2 mRNA
levels are presented in Figure 1B. GATA-1 was ex-
pressed at significantly higher levels (P	 0.013) in GPA
and CD61 cells than in CD34 cells in both controls
(Ct: 3.6  0.4, 4.3  1.1, and 7.0  0.9, respectively)
and IM patients (Ct: 3.0  0.8, 4.0  0.7, and 7.2  2.3,
respectively), with no difference between the two groups
of subjects. GATA-2 mRNA levels were slightly higher in
the CD34 cells than in their differentiated progeny, and
behaved similarly in controls and IM patients: Ct was
3.8  0.8, 5.7  1.0, 4.6  0.9, respectively, in the
CD34, GPA, and CD61 cells of controls, and 3.3 
0.8, 5.6  1.6, 4.2  1.1, respectively, in IM patients.
Finally, approximately comparable FOG-1 mRNA levels
were found in GPA and CD61 cells, which were both
significantly higher than in CD34 cells (P 	 0.035): Ct
was 4.4  0.9, 5.1  1.0, 8.6  1.7, respectively, in the
controls and 3.5  0.3, 4.4  0.9, and 7.6  1.4, respec-
tively, in IM patients.
The human GATA-1 mRNA exists as a full-length and a
short-length transcript, whose relative ratio might be rel-
evant for the control of megakaryocyte proliferation and
differentiation.39 To evaluate whether both isoforms were
transcribed in IM patients, we performed a RT-PCR using
primers that allow the contemporary amplification of both
transcripts. Results presented in Figure 1C show that no
obvious differences in the amplification profile of the two
GATA-1 mRNAs could be demonstrated in cells isolated
from IM patients as compared to controls. Finally, to
check for possible mutations in the coding sequence of
the GATA-1 gene, GATA-1 exons 1 to 6 were amplified
and directly sequenced using DNA isolated from CD34
cells from seven IM patients and four normal controls. In
all cases, the resulting sequences were identical to those
published (National Cancer Institute; accession number,
NM 002049).
Figure 2.Western blot analysis of GATA-1 and GATA-2 protein in purified
CD34, GPA, and CD61 cells obtained from IM patients and controls. A:
Due to the low amount of protein recovered, pools of three IM patients or
four controls were prepared by mixing equal numbers of cells purified from
each patient. A representative blot from one normal and one IM pool is
shown in A, while the percentage changes of GATA-1 and GATA-2 protein
content in the three IM pools (as compared to the two control pools), after
normalization for the actin content, is shown in B. Horizontal lines indicate
the mean values. *P 	 0.02. Films in A were exposed for different times (5
minutes for GATA-1 and GATA-2, 45 seconds for actin).
Figure 1. Analysis of GATA-1 mRNA in CD34 cells purified from the
peripheral blood of IM patients or the BM of controls, and in their erythroid
(GPA) or megakaryocyte (CD61) progeny obtained in vitro. A: Purity of
the isolated cell fractions (CD34, GPA, CD61, from the left) was re-
evaluated by fluorescence-activated cell sorting analysis (top), whereas
morphological appearance was assessed on May-Gru¨mwald/Giemsa-stained
cytosmears (bottom). B: Quantification of GATA-1, GATA-2, and FOG-1
mRNA levels by real-time RT-PCR analysis. A total of 8 controls (for all
different cell populations), and 12, 11, and 10 IM patients, respectively, for
CD34, GPA, and CD61 cells were analyzed. Results are expressed as
mean (SD; each sample assayed in triplicate) Ct for each target gene after
normalization for the amplification level of the housekeeping GAPDH gene;
lower Ct values indicate higher target gene expression levels. C: RT-PCR
amplification of the full-length (GATA-1f) and the shorter (GATA-1s)
GATA-1 transcript starting from mRNA of CD34, GPA, and CD61 cells.
The results are representative of those obtained with cells purified from a
total of four controls and seven IM patients. Amplicons were analyzed during
the exponential phase of PCR (cycles 	 31). The lane on the left contains
molecular weight markers (marker IX).
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Because the above results indicated that the transcrip-
tional activity of neither GATA-1, GATA-2, or FOG-1 is
impaired in any of the cellular populations examined, we
searched for possible alterations in the posttranscrip-
tional processing of GATA-1 (and of GATA-2, as control)
by analyzing content of these proteins by Western blot
analysis. A band of the expected molecular weight for the
full-length GATA-1 ( 46 kd) was detected in all purified
cell populations obtained from IM patients and normal
donors (Figure 2A), unlike the shorter transcript that was
hardly discernible using an anti-C-terminus antibody (not
shown in detail). However, the amount of GATA-1 in
megakaryocytes from IM patients was significantly lower
(by 44  12%, P 	 0.02) than in the corresponding cells
from normal donors, while the content of the protein in
CD34 and GPA cells was approximately comparable
to control (Figure 2B). The GATA-2 content was also
evaluated in the same cell preparations, and found sim-
ilar in cells from IM patients and healthy subjects (Figure
2, A and B), suggesting that the reduced GATA-1 content
in IM megakaryocytes might reflect a selective alteration
in its posttranscriptional processing in these cells.
To rule out that the reduced protein levels in IM
megakaryocytes might be limited to cells obtained in
culture, the GATA-1 content in ex vivo BM megakaryo-
cytes was evaluated by immunohistochemistry. We used
core biopsies obtained from 17 IM patients (patients 1 to
8 of Table 1, plus an additional 9 randomly selected
patients’ biopsies from the repository of our institutions)
and 10 patients with solid neoplasia but no evidence of
BM involvement (normal controls). Because megakaryo-
cyte hyperproliferation, a hallmark of IM, can also be
found in two other Philadelphia-negative CMPDs, PV and
ET, BM biopsies from 10 patients with either of these
diseases were analyzed as well.
In control samples, GATA-1 immunoreactivity was re-
producibly appreciated in the nucleus of all morpholog-
ically recognizable megakaryocytes (Figure 3A); a faint
stain could also be observed in the cytoplasm, irrespec-
tive of the degree of cell maturity. On the contrary, the
staining pattern of megakaryocytes from IM patients
was clearly less homogeneous, because 44.5% of
megakaryocytes (range, 18 to 67%) failed to stain with
GATA-1 antibody, or showed very faint nuclear/cyto-
plasm staining (Figure 3; B, E, and G), as compared to
2.1% (range, 0 to 5) found in normal subjects (P 	 0.01)
(Figure 3, A and E). These GATA-1neg megakaryocytes
could be found scattered in the BM, and were often quite
close to strongly stained megakaryocytes within the
same cluster (Figure 3B). On the other hand, early ery-
throid cells from both normal donors and IM patients
showed strong staining (Figure 3, F and G). GATA-1neg
megakaryocytes were detected only occasionally in ET
patients (4.0%, range, 1 to 13), whereas, interestingly,
they were increased, although not significantly, in some
patients with PV (11.0%, range, 1 to 25) (Figure 3; C to E).
Finally, the staining pattern of FOG-1 in the same BM
samples used for GATA-1 staining was also evaluated.
Representative images are presented in Figure 4, and
show that virtually all IM megakaryocytes (Figure 4B) as
well as those from controls (Figure 4A) and PV or ET
patients (Figure 4, C and D), had a strong uniform stain-
ing for FOG-1 both in the nucleus and the cytoplasm.
We finally evaluated the JAK2 mutational status in 14 of
the 17 patients with IM whose biopsies were available for
the study, and in each of the 10 patients with either PV or
ET, with the aim to search for any correlation with GATA-1
expression. As shown in Figure 5, 10 of 14 IM patients
presented the JAK2 mutation using an allele-specific
PCR approach, as compared to 6 of 10 and 5 of 10 for PV
or ET, respectively;16 none of 20 normal subjects used as
controls had the JAK2 mutation. However, there was no
correlation between the presence of JAK2 mutation and
the percentage of GATA-1neg megakaryocytes in BM
biopsies (Figure 5D).
Discussion
The mechanisms underlying the aberrant proliferation of
hematopoietic cells in Philadelphia-negative CMPDs, in-
cluding PV, ET, and IM, have remained primarily un-
known, notwithstanding a number of cellular abnormali-
ties have been well characterized. However, the recent
description of an acquired mutation of the JAK2
gene,16–18 which has been found in a variable proportion
Figure 4. Immunohistochemistry analysis of FOG-1 in BM biopsies from
controls (A) or patients with IM (B), PV (C), or ET (D). Megakaryocytes and
rare erythroid cells appear strongly and similarly stained with FOG-1 anti-
body. Original magnifications, 400.
Figure 3. Immunohistochemistry analysis of GATA-1 in BM biopsies from IM patients (B, G) or controls (A, F). In A, all morphologically recognizable
megakaryocytes (filled arrows) are strongly stained in the nucleus, with some cytoplasmic staining. On the other hand, the heterogeneity typically observed in
IM samples, with a combination of megakaryocytes normally stained (filled arrows) or showing no to very faint nucleus/cytoplasmic staining (open arrows)
(GATA-1neg megakaryocytes) can be appreciated in B. The staining pattern in PV or ET patients is shown in C and D, respectively. The percentage of GATA-1neg
megakaryocytes in controls (n 	 10) and in patients with either IM (n 	 17), ET, or PV (n 	 10 for both) is shown in E. Early erythroid cells in a typical erythroid
island of a normal patient (F) are heavily stained, whereas more mature erythroblasts show weaker staining; the same pattern can be appreciated in the section
from an IM patient (G), in which GATA-1pos erythroblasts appear surrounded by GATA-1neg megakaryocytes (open arrows). Original magnifications, 200.
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of patients with the different clinical forms of CMPD, will
probably permit a more focused approach to disease
pathogenesis in the near future. Among CMPDs, IM is
characterized by well-defined and specific alterations in
the proliferation and differentiation of megakaryocytes.
Mutations in the GATA-1 gene have recently been asso-
ciated with inherited40 and acquired41 human patholo-
gies that present defective megakaryocytopoiesis; the
latter include the transient myeloproliferative disorder of
the newborn, the megakaryoblastic leukemia of Down
syndrome, and at least a sporadic case of megakaryo-
blastic leukemia.42 These diseases are also character-
ized by a conspicuous BM fibrosis that accompanies the
proliferation of abnormal megakaryocyte precursors. In-
terestingly, a role for defective GATA-1 expression in the
pathogenesis of IM has been advocated following the
observation that the GATA-1low mutation induces in
mice a syndrome that recapitulates several aspects of
the human disease.
Our aim was to clarify whether megakaryocytes from
IM patients would present abnormalities in GATA-1. To
this end, and owing the difficulties in obtaining ex vivo
megakaryocytes from the BM that is almost invariably
inaspiratable in the fibrotic stage of disease, CD34 cells
were purified from the peripheral blood and induced to
differentiate toward either the erythroid (as control) or the
megakaryocytic lineage in vitro. Levels of GATA-1 mRNA
and protein were analyzed in highly purified early hema-
topoietic progenitors cells (CD34), as wells as in their
erythroid (GPA) and megakaryocytic (CD61) progeny.
The results were compared with those obtained with the
corresponding cell populations from healthy donors. The
levels of GATA-1 mRNA, as measured by a sensitive
real-time PCR assay, resulted similar to controls in any of
the cell populations analyzed, as well as it was the con-
tent of both GATA-2 and FOG-1 mRNA. Although no data
concerning GATA-2 expression in IM has yet been pub-
lished to the best of our knowledge, our results differ from
those of Martyre` and colleagues34 who reported in-
creased expression of FOG-1 in peripheral blood CD34
cells using a semiquantitative PCR technique unlike a
real-time RT-PCR assay as we did; these technical differ-
ences might at least partially help to explain these dis-
crepancies. On the contrary, GATA-1 protein content by
Western blot analysis was significantly reduced in
megakaryocytes obtained from IM patients, but not in
their CD34 or GPA cells. Most significantly, the reduc-
tion in GATA-1 content in IM megakaryocytes was not
dependent on in vitro culture conditions, because the
levels of both mRNA and protein for GATA-2 were other-
wise normal. Furthermore, immunohistochemical analy-
ses on core biopsies confirmed that also ex vivo
megakaryocytes from IM patients contain reduced levels
of GATA-1 protein, while they normally express FOG-1.
These data support the contention that megakaryocytes
from IM patients show defects in term of low GATA-1
content similar to the megakaryocytes from GATA-1low
mice, and reinforce the view that this abnormality might
represent a key event involved in the pathogenesis of the
disease. However, although in GATA-1low mice defective
GATA-1 expression is the consequence of the deletion
of megakaryocytic-specific regulatory sequences, the
mechanism(s) responsible for the reduced levels of
GATA-1 protein in IM megakaryocytes are less clear,
owing to the normal mRNA levels found in these cells.
Because mutations were not detected in the coding re-
gion of GATA-1, we can predict a normal primary and
secondary structure of the protein, making unlikely
changes in the phosphorylation or acetylation status that
may affect its half-life. Furthermore, because the full-
length and the short-length GATA-1 mRNA isoforms were
both transcribed in normal ratio, but only the full-length
GATA-1 protein was detectable by Western blots in both
IM and controls also using an antibody that recognizes
the C-terminus of the protein, the mechanisms leading to
abnormal megakaryocytopoiesis in IM are clearly differ-
ent from those implicated in the Down-associated
megakaryoblastic leukemia, in which the shorter tran-
script is prevalent or absolute. These considerations
point to a defect in trans to the GATA-1 gene as the most
likely mechanism underlying the deficiency of GATA-1
protein in IM megakaryocytes; this might involve a
GATA-1 partner still to be identified, that would prevent
GATA-1 degradation by the proteosome machinery of the
megakaryocytes. These aspects are being addressed in
ongoing studies.
The observation that, among CMPD patients, defective
GATA-1 staining was consistently associated with
megakaryocytes from IM patients, and not with those
from either PV or ET patients, not only stresses the spec-
ificity of the observation, but also suggests that GATA-1
staining of core biopsies might represent a diagnostic
tool to discriminate IM, and eventually the prefibrotic
stages of disease, from the other CMPDs. In this regard,
it is interesting that some of PV patients showed in-
creased frequencies of GATA-1neg megakaryocytes; al-
though this difference was not statistically significant, it
might point to a subgroup of PV patients that would
eventually evolve to IM. Prospective studies are required
to confirm this hypothesis.
Recently, a point mutation in exon 12 of JAK2 kinase
has been described as a molecular lesion shared by
the different clinical entities of Philadelphia-negative
CMPDs.16–18 We found that 10 of 14 IM patients (76%)
evaluated carried this mutation, as well as 60% and 50%
Figure 5. JAK2 mutation analysis in patients with IM (A), PV (B), or ET (C).
The presence of the Val617Phe JAK2 mutation was analyzed by an allele-
specific PCR; the 203-bp product is specifically amplified from the mutant
allele, while the 364-bp product serves as an internal control for both mutant
and normal allele. The percentage of GATA-1neg megakaryocytes according
to the presence or not of JAK2 mutation is reported in D.
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of 10 patients with either PV or ET, respectively. The
Val617Phe mutation results in constitutive tyrosine phos-
phorylation activity because of the disruption of the au-
toinhibitory activity of JAK2,17 thereby promoting cyto-
kine hypersensitivity. Because GATA-1 may be a
downstream target of JAK2 after the binding of TPO to its
receptor c-MPL, we aimed at correlating the presence or
not of the JAK2 mutation with the percentage of GATA-
1neg megakaryocytes in BM biopsies. Results obtained
do not actually support a downstream pathogenetic re-
lationship between JAK2 mutation and the abnormalities
in GATA-1 content in megakaryocytes.
In summary, the data presented demonstrate that
megakaryocytes from patients with IM contain reduced
levels of GATA-1 protein, and suggest that this abnormal-
ity is specifically disease-associated and might play a
role in its pathogenesis.
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